Cover ImageSALE
市場調查報告書

黏多醣症的基因治療市場:開發平台分析報告

Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 609181
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Back to Top
黏多醣症的基因治療市場:開發平台分析報告 Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report
出版日期: 2018年02月27日 內容資訊: 英文 83 Pages
簡介

本報告提供前臨床及其他各種發展階段的分子,黏多醣症的基因治療的臨床試驗形勢的詳細洞察。還有含給藥途徑的各種市場區隔為基礎開發平台分子的治療評估相關全面性資訊。

本報告處理的項目

  • 黏多醣症的各種發展階段的基因治療分子
  • 現在從事黏多醣症的基因治療分子開發的企業
  • 來自恰當推論的中斷/惰性分子的洞察
  • 批准藥的主要法規當局(各地區)
  • 各活性分子詳細的分析

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 黏多醣症的基因治療:洞察

  • 簡介
  • 主要法規當局
  • 美國
  • 歐洲
  • 日本
  • 澳洲
  • 中國

第5章 開發平台的風景

第6章 比較分析

  • 中期分子(階段I / II)
  • 初期階段的分子(pre-IND及IND)
  • 前臨床階段的分子
  • 懸浮分子

第7章 表示分析

第8章 治療評估:各ROA

第9章 主要企業

  • 活躍的企業:範疇與參數
  • 附錄
  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR20377

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for mucopolysaccharidosis including molecules at pre-clinical and various other development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations including route of administration

Key questions answered in the report include:

  • What are the gene therapy molecules in the various development stages for mucopolysaccharidosis?
  • What are the companies that are currently involved in the development of gene therapy molecules for mucopolysaccharidosis?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?

Detailed profiling of each active molecule.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR MUCOPOLYSACCHARIDOSES: AN INSIGHT

  • Introduction
  • MAJOR REGULATORY AUTHORITIES
  • US
  • Europe
  • Japan
  • Australia
  • China

PART 05: PIPELINE LANDSCAPE

PART 06: COMPARATIVE ANALYSIS

  • Mid-stage molecules (Phase I/II), 2017
  • Early-stage molecules (pre-IND and IND), 2017
  • Pre-clinical stage molecules, 2017
  • Suspended molecule, 2017

PART 07: INDICATION ANALYSIS

PART 08: THERAPEUTIC ASSESSMENT BY ROA

PART 09: KEY COMPANIES

  • Active companies: Category and parameters
  • APPENDIX
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Drug approval process by US FDA
  • Exhibit 02: Pipeline molecules (active) by vendors
  • Exhibit 03: Pipeline landscape
  • Exhibit 04: Pipeline molecules in different developmental stages 2017
  • Exhibit 05: Percentage of pipeline molecules in different developmental stages 2017
  • Exhibit 06: Overview: ABO-101
  • Exhibit 07: Clinical trials description of ABO-101
  • Exhibit 08: Overview: ABO-102
  • Exhibit 09: Clinical trials description of AB0-102
  • Exhibit 10: Overview: SAF-301
  • Exhibit 11: Clinical trials description of SAF-301
  • Exhibit 12: Overview: SAF302
  • Exhibit 13: Overview: SB-913
  • Exhibit 14: Clinical trials description of SB-913
  • Exhibit 15: Overview: SB-318
  • Exhibit 16: Clinical trials description of SB-318
  • Exhibit 17: Overview: EGT-101
  • Exhibit 18: Clinical trials description of EGT-101
  • Exhibit 19: Overview: Autologous ex-vivo lentiviral gene therapy
  • Exhibit 20: Overview: RGX-111
  • Exhibit 21: Overview: RGX-121
  • Exhibit 22: Overview: EGT-201
  • Exhibit 23: Overview: EGT-301
  • Exhibit 24: Overview: Gene therapy for mucopolysaccharidosis I (Hurler's syndrome)
  • Exhibit 25: Overview: SOBI003
  • Exhibit 26: Suspended molecule, 2017
  • Exhibit 27: Analysis by type of indication
  • Exhibit 28: Assessment by RoA
  • Exhibit 29: Assessment of gene therapy for mucopolysaccharidosis by stage and RoA
  • Exhibit 30: Active companies: Category and parameters 2017
  • Exhibit 31: Segmentation of companies 2017
  • Exhibit 32: Overview: Abeona Therapeutics
  • Exhibit 33: Overview: ESTEVE
  • Exhibit 34: Overview: Immusoft
  • Exhibit 35: Overview: Lysogene
  • Exhibit 36: Overview: Orchard Therapeutics
  • Exhibit 37: Overview: REGENXBIO
  • Exhibit 38: Overview: Sangamo Therapeutics
  • Exhibit 39: Overview: Swedish Orphan Biovitrum
  • Exhibit 40: Overview: uniQure
Back to Top